Introducing: VirusHunter – A single test for detection and identification of any potentially pathogenic virus 

Have you ever wondered whether you can get infected with a virus in an elevator? The answer is yes. Do you know whether it is possible to detect any virus? For now, no. The VirusHunter team is developing a kit for the detection and identification of any potentially pathogenic virus—a solution that currently does not exist on the market. In less than 24 hours, they can tell you whether you have a virus and which virus it is, without the need for specific antibodies or primers.

The intensive changes in nature caused by climate change and human activity are resulting in rapid adaptation of microorganisms, especially viruses. Depending on their ability to spread among humans, a new virus can cause sporadic cases that may lead to localized outbreaks or, in the worst-case scenario, a global pandemic requiring public health intervention. The number of potential viral pathogens in the world is extremely large, while the resources for research and development of methods for their identification are limited. The World Health Organization, in the context of public health needs, has compiled a list of priority pathogens for research and encourages the development of identification methods. This list also includes “Disease X,” caused by an unknown pathogen, highlighting the high likelihood—especially after the COVID-19 pandemic—that new pandemics caused by unknown pathogens will appear in the future. Therefore, detecting an unknown viral pathogen that could potentially cause disease in humans is of exceptional importance, as it can enable timely identification before a pandemic begins and, in the best-case scenario, even prevent it. 

Identifying the causative agent is a prerequisite for treating patients with a viral disease.  Today, due to the growing understanding of the negative effects even of viruses not considered dangerous in healthy individuals, as well as the asymptomatic spread of some viruses—which poses a risk to immunocompromised, pediatric and geriatric patients—accurate virus identification is becoming extremely important. Antiviral drugs are being developed rapidly, and for them it is crucial that therapy begins as early as possible, yet their use is limited precisely because of the difficulties in quickly identifying viruses in patients. 

A common drawback of currently available viral identification tests is the fact that the specific type of virus must be known beforehand—meaning the physician must decide in advance which virus to test the patient for. In other words, testing is performed only for targeted viruses, not for a test that would identify, out of all viruses in the sample, the one causing the disease. When, after performing one or more viral tests, no answer is found, time and money have been wasted. Statistical data show that among viral-suspected infections in children, as many as 38% of respiratory, 43% of gastrointestinal and 40% of encephalitis cases remain unidentified by available protocols. What if there were a universal test for the detection and identification of any virus? 

VirusHunter is a test that makes exactly that possible. It answers the question of whether a virus is present in a sample and, if so, identifies which virus it is. In the end, this means that the test result is not “positive” or “negative”—the test result is the identified virus. Another advantage of the VirusHunter test is that it identifies only those viruses that are potentially pathogenic, and it can identify both known and completely new, unknown viruses. 

Illustration of the use of the VirusHunter method for identifying any potentially pathogenic virus in humans

 

The VirusHunter test is primarily intended for physicians who will be able to use this technology for the rapid detection and identification of viruses in order to diagnose and recommend appropriate treatment, thereby reducing the spread of viruses in the population. It is particularly important that the use of this test would enable timely administration of antiviral drugs and reduce unnecessary antibiotic use, which is often prescribed “just in case.” A possible outcome is increased patient trust in physicians. With widespread use of VirusHunter, data extremely valuable to epidemiologists would be collected for monitoring viral pathogens in the population, enabling early intervention, effective surveillance and informed decision-making in response to new viral threats. VirusHunter will, for the first time, enable a proactive approach to discovering and identifying viruses, revolutionizing global public health protection. 

Team members

The VirusHunter team consists of Andreja Ambriović Ristov and Dragomira Majhen, who have been researching viruses together at the Ruđer Bošković Institute for over 20 years. 

Andreja and Dragomira began working on VirusHunter in 2016 with the support of funds awarded through the Proof of Innovative Concept (PoC6) call issued by HAMAG-BICRO, during which they confirmed the concept. They will continue further method development thanks to non-repayable funds from the “Support for Technology Transfer” project, financed by the National Recovery and Resilience Plan. The program supports the implementation of research and development activities for the purpose of developing or further improving developed solutions and technical validation before commercialization. This should result in the creation of a minimum viable product that could be tested in a real-world setting, which in this case would be family medicine practices or infectious disease clinics. 

Team members from left to right: Andreja Ambriović Ristov, Dragomira Majhen

 

Dr. Andreja Ambriović Ristov, scientific advisor in permanent title, is the head of the Laboratory for Cell Biology and Signal Transduction at the Ruđer Bošković Institute and was until recently the head of the Division of Molecular Biology. She was a member of the Scientific Council of the Government of the Republic of Croatia for combating the COVID-19 pandemic. She is an expert in adenoviral vectors used for COVID-19 vaccination and in recent years has worked more intensively on researching adhesion proteins in tumor cells and their role in the sensitivity of tumor cells to chemotherapy. She has many years of experience leading scientific projects and exceptionally rich methodological expertise, which, together with virology knowledge, was crucial for the conceptual development of the VirusHunter method. Details about her scientific work are available on her website. 

Dr. Dragomira Majhen is a scientific advisor employed in the Laboratory for Cell Biology and Signal Transduction at the Ruđer Bošković Institute. She was a member of the international Vaccine Sputnik V advisory board (Scientific Advisory Board on the Sputnik V vaccine) and a scientist at the biopharmaceutical company Johnson & Johnson in the Netherlands. She is an expert in adenoviral vectors for gene transfer and vaccination. She has extensive project-leading experience and has attended several intensive educational programs on knowledge and technology transfer (EIT Jumpstarter, Big Bang Camp, commercialization of RDI results for experienced researchers), receiving awards in the process. Details about her scientific work are available on her website. 

Motivation for Applying and Vision for the End of the Nuqleus Program

Since our ultimate goal is to commercialize VirusHunter technology by developing a commercial test for the detection and identification of any potentially pathogenic human virus, we decided to gain education in knowledge commercialization. Applying to the Nuqleus program is an ideal opportunity to participate in a series of workshops and lectures aimed at acquiring the knowledge and skills necessary for market research, presenting an idea to the business world, designing a business model, communicating with investors and transitioning VirusHunter from a research environment to a diagnostic laboratory. Nuqleus represents a crystallization center for all those who, like us, wish to transfer their knowledge and ideas to society. 

By the end of the Nuqleus program, we aim to create a clear business model that will enable the successful introduction of the VirusHunter test into practice. 

03/06/2024